MDM2 antagonism by nutlin-3 induces death in human medulloblastoma cells

Neuroscience Letters

Volumn 513, Issue 1, 2012, Pages 106-110

  Ghassemifar, Sara ^a   Mendrysa, Susan M ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

Apoptosis; MDM2; Medulloblastoma; TP53

Indexed keywords

DNA; DOXORUBICIN; NUTLIN 3; PROTEIN MDM2; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER CELL; CELL DEATH; CELL GROWTH; CONTROLLED STUDY; DRUG POTENTIATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MEDULLOBLASTOMA; PRIORITY JOURNAL; WILD TYPE;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL CYCLE; CELL DEATH; CELL LINE, TUMOR; COLORING AGENTS; DOXORUBICIN; HUMANS; IMIDAZOLES; MEDULLOBLASTOMA; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-MDM2; TETRAZOLIUM SALTS; THIAZOLES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84858150408     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2012.02.022     Document Type: Article

References (36)

1. Adesina A.M., Nalbantoglu J., Cavenee W.K. p53 gene mutation and mdm2 gene amplification are uncommon in medulloblastoma. Cancer Research 1994, 54:5649-5651.
2. Badiali M., Iolascon A., Loda M., Scheithauer B.W., Basso G., Trentini G.P., Giangaspero F. p53 gene mutations in medulloblastoma. Immunohistochemistry, gel shift analysis, and sequencing. Diagnostic Molecular Pathology 1993, 2:23-28.
3. Carvajal D., Tovar C., Yang H., Vu B.T., Heimbrook D.C., Vassilev L.T. Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. Cancer Research 2005, 65:1918-1924.
4. Chen L., Agrawal S., Zhou W., Zhang R., Chen J. Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:195-200.
5. De Preter K., Speleman F., Combaret V., Lunec J., Laureys G., Eussen B.H., Francotte N., Board J., Pearson A.D., De Paepe A., Van Roy N., Vandesompele J. Quantification of MYCN, DDX1, and NAG gene copy number in neuroblastoma using a real-time quantitative PCR assay. Modern Pathology 2002, 15:159-166.
6. El-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993, 75:817-825.
7. Fiorillo A., Maggi G., Martone A., Migliorati R., D'Amore R., Alfieri E., Greco N., Cirillo S., Marano I. Shunt-related abdominal metastases in an infant with medulloblastoma: long-term remission by systemic chemotherapy and surgery. Journal of Neuro-Oncology 2001, 52:273-276.
8. Giordana M.T., Duo D., Gasverde S., Trevisan E., Boghi A., Morra I., Pradotto L., Mauro A., Chio A. MDM2 overexpression is associated with short survival in adults with medulloblastoma. Neuro Oncology 2002, 4:115-122.
9. Hainaut P., Hollstein M. p53 and human cancer: the first ten thousand mutations. Advances in Cancer Research 2000, 77:81-137.
10. Haupt Y., Maya R., Kazaz A., Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997, 387:296-299.
11. Hollstein M., Sidransky D., Vogelstein B., Harris C.C. p53 mutations in human cancers. Science 1991, 253:49-53. New York, NY.
12. Iwakuma T., Lozano G. MDM2, an introduction. Molecular Cancer Research 2003, 1:993-1000.
13. Kaufmann S.H., Desnoyers S., Ottaviano Y., Davidson N.E., Poirier G.G. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Research 1993, 53:3976-3985.
14. Kubbutat M.H., Jones S.N., Vousden K.H. Regulation of p53 stability by Mdm2. Nature 1997, 387:299-303.
15. Lane D.P., Fischer P.M. Turning the key on p53. Nature 2004, 427:789-790.
16. Lee J.H., Kang Y., Khare V., Jin Z.Y., Kang M.Y., Yoon Y., Hyun J.W., Chung M.H., Cho S.I., Jun J.Y., Chang I.Y., You H.J. The p53-inducible gene 3 (PIG3) contributes to early cellular response to DNA damage. Oncogene 2010, 29:1431-1450.
17. Lowe S.W., Ruley H.E., Jacks T., Housman D.E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993, 74:957-967.
18. Malek R., Matta J., Taylor N., Perry M.E., Mendrysa S.M. The p53 inhibitor MDM2 facilitates sonic Hedgehog-mediated tumorigenesis and influences cerebellar foliation. PLoS ONE 2011, 6:e17884.
19. Miyashita T., Krajewski S., Krajewska M., Wang H.G., Lin H.K., Liebermann D.A., Hoffman B., Reed J.C. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994, 9:1799-1805.
20. Momand J., Jung D., Wilczynski S., Niland J. The MDM2 gene amplification database. Nucleic Acids Research 1998, 26:3453-3459.
21. Momand J., Zambetti G.P., Olson D.C., George D., Levine A.J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992, 69:1237-1245.
22. Nakano K., Vousden K.H. PUMA, a novel proapoptotic gene, is induced by p53. Molecular Cell 2001, 7:683-694.
23. Northcott P.A., Korshunov A., Witt H., Hielscher T., Eberhart C.G., Mack S., Bouffet E., Clifford S.C., Hawkins C.E., French P., Rutka J.T., Pfister S., Taylor M.D. Medulloblastoma comprises four distinct molecular variants. Journal of Clinical Oncology 2010, 29:1408-1414.
24. Pattyn F., Robbrecht P., De Paepe A., Speleman F., Vandesompele J. RTPrimerDB: the real-time PCR primer and probe database, major update 2006. Nucleic Acids Research 2006, 34:D684-D688.
25. Rickert C.H., Paulus W. Epidemiology of central nervous system tumors in childhood and adolescence based on the new WHO classification. Childs Nervous System 2001, 17:503-511.
26. Roussel M.F., Hatten M.E. Cerebellum development and medulloblastoma. Current Topics in Developmental Biology 2011, 94:235-282.
27. Soussi T. p53 alterations in human cancer: more questions than answers. Oncogene 2007, 26:2145-2156.
28. Stuhmer T., Chatterjee M., Hildebrandt M., Herrmann P., Gollasch H., Gerecke C., Theurich S., Cigliano L., Manz R.A., Daniel P.T., Bommert K., Vassilev L.T., Bargou R.C. Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood 2005, 106:3609-3617.
29. Tabori U., Baskin B., Shago M., Alon N., Taylor M.D., Ray P.N., Bouffet E., Malkin D., Hawkins C. Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations. Journal of Clinical Oncology 2010, 28:1345-1350.
30. Van Maerken T., Ferdinande L., Taildeman J., Lambertz I., Yigit N., Vercruysse L., Rihani A., Michaelis M., Cinatl J., Cuvelier C.A., Marine J.C., De Paepe A., Bracke M., Speleman F., Vandesompele J. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53. Journal of the National Cancer Institute 2009, 101:1562-1574.
31. Van Maerken T., Speleman F., Vermeulen J., Lambertz I., De Clercq S., De Smet E., Yigit N., Coppens V., Philippe J., De Paepe A., Marine J.C., Vandesompele J., Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma. Cancer Research 2006, 66:9646-9655.
32. Vassilev L.T. MDM2 inhibitors for cancer therapy. Trends in Molecular Medicine 2007, 13:23-31.
33. Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., Kong N., Kammlott U., Lukacs C., Klein C., Fotouhi N., Liu E.A. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303:844-848. New York, NY.
34. Walter A.W., Mulhern R.K., Gajjar A., Heideman R.L., Reardon D., Sanford R.A., Xiong X., Kun L.E. Survival and neurodevelopmental outcome of young children with medulloblastoma at St Jude Children's Research Hospital. Journal of Clinical Oncology 1999, 17:3720-3728.
35. Wasylyk C., Salvi R., Argentini M., Dureuil C., Delumeau I., Abecassis J., Debussche L., Wasylyk B. p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53. Oncogene 1999, 18:1921-1934.
36. Zhang F., Tagen M., Throm S., Mallari J., Miller L., Guy R.K., Dyer M.A., Williams R.T., Roussel M.F., Nemeth K., Zhu F., Zhang J., Lu M., Panetta J.C., Boulos N., Stewart C.F. Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration. Drug Metabolism and Disposition: The Biological Fate of Chemicals 2011, 39:15-21.